Appili Therapeutics Announces New Patents Granted for Commercial Stage Asset LIKMEZ®(TM)

Stock Information for Appili Therapeutics Inc

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Appili Therapeutics Inc

Appili Therapeutics Announces Formal Termination of Arrangement Agreement with Aditxt Inc.
Appili Therapeutics Provides Update on Arrangement with Aditxt, Inc.
Appili Therapeutics and Colleagues Publish Manuscript on the Prevention and Emergency Response to Tularemia
Appili President and CEO, Don Cilla to Join Aditxt CEO, Amro Albanna for Aditxt Weekly Update on April 4, 2025
Appili Therapeutics Announces Submission of U.S. Federal Government Funding Proposals and Provides Corporate and Aditxt Transaction Update
Appili Therapeutics Reports Financial and Operational Results for Third Quarter of Fiscal Year 2025
Aditxt's Subsidiary Adimune Successfully Completes Preclinical Efficacy and Safety Studies for Its Immune Modulation Therapeutic ADI Platform, Advancing Toward First-in-Human Clinical Trials
Appili Therapeutics Announces Receipt of Final Court Order for Arrangement with Aditxt, Inc.

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.